More on CYTR

- Summary
- Chart
- Profile
- Historical


- Earnings (-10.0% Growth)
- Ratings (8.3 Score)
- Holders


Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (2/4/16 *Est.)


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

CYTR Balance Sheet

Click line-items for a historical chart and %
Current assets:
Cash and cash equivalents 22.26M
Marketable securities 35.04M
Proceeds from sale of RXi, received January 6, 2011
Receivable 4.59M
Investment in Adventrx Pharmaceuticals, at market
Income taxes recoverable
Interest receivable 28.13K
Prepaid expenses and other current assets 2.37M
Total current assets 64.29M
Equipment and furnishings, net 1.47M
Goodwill 183.78K
Other assets 1.08M
Total assets 67.02M
Current liabilities:
Accounts payable 8.06M
Accrued expenses and other current liabilities 9.69M
Warrant liabilities 693.46K
Total current liabilities 22.95M
Stockholders' equity:
Preferred Stock, $.01 par value, 5,000,000 shares authorized, including 15,000 shares of Series A Junior Participating Preferred Stock; no shares issued and outstanding 0
Common stock, $.001 par value, 175,000,000 shares authorized; 109,857,885 and 109,840,445 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively 66.48K
Additional paid-in capital 409.11M
Accumulated comprehensive income, net of tax
Treasury stock, at cost (633,816 shares) 0
Accumulated deficit -365.09M
Total stockholders' equity 44.08M
Total liabilities and stockholders' equity 67.02M